Schrodinger (SDGR) PT Raised to $117 at BMO Capital

BMO Capital analyst Do Kim raised the price target on Schrodinger (NASDAQ: SDGR) to $117.00 (from $97.00) while maintaining an Outperform rating.

The analyst commented, "We raise our target price to $117 from $97, as we increase drug discovery revenues to reflect higher economics for internal programs based on favorable SDGR4/5 licensing terms in the BMS agreement. We expect IND-enabling studies for at least one internal program (CDC7, WEE1, MALT1) in 1H21, supporting a potential first-in-human study in 1Q22. On the software side, we expect 4Q20 step-up due to seasonality, with upward licensing revisions supporting growing adoption and maintaining positive momentum heading into 2021."

You May Also Be Interested In

• RBC Capital Downgrades Range Resources (RRC) to Sector Perform
• Morgan Stanley Upgrades EPAM Systems (EPAM) to Equalweight
• Neste Oyj (NESTE:FH) (NTOIY) PT Lowered to EUR28 at Barclays